samedan logo

 
 
spacer
home > ebr > spring 2017 > balancing act
PUBLICATIONS
European Biopharmaceutical Review

Balancing Act

Escherichia coli has been the historical workhorse for the production of therapeutic proteins since the first biologic, insulin, hit the market in 1982. It continues to be a preferred system, because operations are inexpensive and timelines are short. Pharmaceutical companies tune the fermentation procedure for the greatest yield in every batch by maximising the cell density per batch and per cell expression. Peak cell density is obtained through process optimisation, and maximal specific productivity is achieved by strain/vector engineering.

These two activities require different research skillsets and are often performed independently of each other. Small virtual companies with preclinical programmes often separate these activities by outsourcing them to different firms. One service provider develops a strain, which is then transferred to a contract manufacturing organisation to maximise the cell density in order to enable the isolation of sufficient product to file an investigational new drug and support Phase 1 and 2 trials.

Such strategies often rely on the assumption that fine-tuning the process can occur during early clinical development. The downfall, however, occurs when fermentation cannot be significantly improved without genetic engineering of the strain. Creation of an entirely new master cell bank constitutes a major procedure change that means going ‘back to the drawing board’. If the end goal is to hand the therapeutic to a large pharma company in order to launch a commercial process, then this downfall can represent a considerable decrease in value.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
April Stanley is the Manager of Cell Line and Strain Development at Cytovance, and earned her Master’s Degree from the University of Illinois, US, in Microbiology. During her six years at Cytovance, she has designed the company’s E. coli toolbox and currently leads the team that developed the platform fermentation processes, which match the production strains generated with the toolbox.
spacer
April Stanley
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Oxford BioTherapeutics Announces Research Collaboration with ImmunoGen to Develop Novel Antibody-Drug Conjugates

OXFORD, UK and SAN JOSE, California, 13/06/2022 - Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and Antibody Drug Conjugate (ADC)-based therapies, today announced a multi-year collaboration to research, develop and commercialize novel, first-in-class ADCs with ImmunoGen (IMGN), a leader in the expanding field of ADCs for the treatment of cancer. The companies will utilize ImmunoGen’s linker-payload technology directed to novel targets identified via OBT's proprietary OGAP® discovery platform. The companies will support these R&D efforts through joint funding and by combining their respective proprietary technologies.
More info >>

White Papers

Bio/Pharmaceutical Methods: Do your Analytical Methods Hold Up to Regulatory Scrutiny?

Eurofins BioPharma Product Testing

As FDA guidelines evolve and drug products on the market begin to age, bio/pharmaceutical manufacturers face scrutiny of the original methods used to support these products. Therefore, manufacturers must re-evaluate these methods to ensure they comply with current FDA expectations. Some manufacturers are even facing consent decrees imposed by the agency requiring them to bring methods up to current standards within a specified timeframe. This exercise requires significant amounts of time and resources, which many manufacturers do not have since they are focused on getting their next products to market. For that reason, some clients have been turning to Eurofins Lancaster Laboratories for support.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement